CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40.
Wang R, Graham S, Sun N, McCarthy D, Peng R, Erickson J, Oconnor L, Zhu X, Wurbel M, Dunstan R, Westmoreland S, Chung N, Ghayur T, Gu J.
Wang R, et al. Among authors: sun n.
PLoS One. 2020 Mar 10;15(3):e0228221. doi: 10.1371/journal.pone.0228221. eCollection 2020.
PLoS One. 2020.
PMID: 32155151
Free PMC article.